Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Jul;142(7):1609-19.
doi: 10.1007/s00432-016-2173-9. Epub 2016 May 2.

High-dose radiotherapy with helical tomotherapy and long-term androgen deprivation therapy for prostate cancer: 5-year outcomes

Natsuo Tomita  1 , Norihito Soga  2 , Yuji Ogura  2 , Norio Hayashi  2 , Takumi Kageyama  2 , Makoto Ito  3 , Yutaro Koide  3 , Maiko Yoshida  3 , Kana Kimura  3 , Chiyoko Makita  3 , Hiroyuki Tachibana  3 , Takeshi Kodaira  3
Affiliations

High-dose radiotherapy with helical tomotherapy and long-term androgen deprivation therapy for prostate cancer: 5-year outcomes

Natsuo Tomita et al. J Cancer Res Clin Oncol. 2016 Jul.

Abstract

Purpose: We aimed to examine outcomes of high-dose radiotherapy with helical tomotherapy (HT) and long-term androgen deprivation therapy (ADT) for T1-4N0M0 prostate cancer.

Methods: A total of 391 patients treated with HT between June 2006 and December 2013 were included in this retrospective study. All patients received neoadjuvant ADT for a median duration of 10 months followed by HT at a median dose of 78 Gy [interquartile range (IQR) 78-78]. The times of median adjuvant and total ADT were 19 and 27 months (IQR 20-31), respectively. The risk stratification followed the 2015 National Comprehensive Cancer Network criteria. Biochemical disease-free survival (bDFS) followed the Phoenix definition. Toxicity was scored according to the Radiation Therapy Oncology Group morbidity grading scale.

Results: Median follow-up from HT start was 60 months (IQR 42-81). Five-year bDFS rates for low-, intermediate-, high-, and very-high-risk groups were 100, 98.2, 97.7, and 87.9 %, respectively. We observed clinical relapse in nine very-high-risk patients and one high-risk patient, resulting in a 5-year clinical relapse-free survival of 100, 100, 99.4, and 91.7 %, respectively, for each risk group. Three patients died of prostate cancer, resulting in a 5-year prostate cancer-specific survival of 99.6 %. The late grade 2 or higher gastrointestinal and genitourinary toxicities were 9.7 and 10.7 %. No cardiovascular fatal events were observed.

Conclusions: This report confirmed the excellent outcomes with acceptable late toxicities with the combination of HT and long-term ADT. Longer follow-up is crucial to further determine the treatment effect and toxicity.

Keywords: Androgen deprivation therapy; Helical tomotherapy; Image-guided radiation therapy; Intensity-modulated radiation therapy; Prostate cancer.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1
5-Year biochemical disease-free survival (bDFS) for the low-, intermediate-, high-, and very-high-risk groups
Fig. 2
Fig. 2
5-Year clinical relapse-free survival (cRFS) for the low-, intermediate-, high-, and very-high-risk groups
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Alicikus ZA, Yamada Y, Zhang Z, Pei X, Hunt M, Kollmeier M, Cox B, Zelefsky MJ (2011) Ten-year outcomes of high-dose, intensity-modulated radiotherapy for localized prostate cancer. Cancer 117(7):1429–1437 - PubMed
    1. Amini A, Rusthoven CG, Jones BL, Armstrong H, Raben D, Kavanagh BD (2016) Survival outcomes of radiotherapy with or without androgen-deprivation therapy for patients with intermediate-risk prostate cancer using the National Cancer Data Base. Urol Oncol 34(4):165.e1–165.e9 - PubMed
    1. Berrington de Gonzalez A, Wong J, Kleinerman R, Kim C, Morton L, Bekelman JE (2015) Risk of second cancers according to radiation therapy technique and modality in prostate cancer survivors. Int J Radiat Oncol Biol Phys 91(2):295–302 - PMC - PubMed
    1. Bolla M, de Reijke TM, Van Tienhoven G, Van den Bergh AC, Oddens J, Poortmans PM, Gez E, Kil P, Akdas A, Soete G, Kariakine O, van der Steen-Banasik EM, Musat E, Pierart M, Mauer ME, Collette L (2009) Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 360(24):2516–2527 - PubMed
    1. Bolla M, Van Tienhoven G, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C, Billiet I, Torecilla JL, Pfeffer R, Cutajar CL, Van der Kwast T, Collette L (2010) External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol 11(11):1066–1073 - PubMed

Substances

LinkOut - more resources